Uncategorized
Low-dose atropine eye drops slow progression of myopia in children
LAS VEGAS — A low-dose formulation of atropine slowed the progression of myopia in a 5-year clinical trial, a speaker told colleagues at the American Academy of Ophthalmology meeting here.“We think we can prevent myopic progression both safely and effectively in children for the first time. A 0.01% once-a-day [dose] appears to be able to reduce that amount of progression by about 50%,” Donald Tan, MD, said during a press briefing on “Innovations in vision: Nanotech, nearsightedness and neuro-ophthalmology imaging.”